PARP inhibition leads to synthetic lethality with key splicing-factor mutations in myelodysplastic syndromes.

Our findings suggest that mutant cells antagonise the genome threat caused by R-loop disruption by PARP activation, thus making PARP targeting a promising therapeutic strategy for myeloid cancers with mutations in SRSF2.